ESMO Open
2059-7029
Anh Quốc
Cơ quản chủ quản: Elsevier BV , Elsevier
Phân tích ảnh hưởng
Thông tin về tạp chí
Lĩnh vực:
OncologyCancer Research
he journal aims to publish research in all disciplines, experimental, translational, diagnostic and therapeutic areas related to oncology, including: original articles, reviews, editorials and correspondence. In addition the journal welcomes phase I trials and meta-analyses, and will also publish reviews from important European Society for Medical Oncology (ESMO) conferences and meetings as well as position statements on behalf of ESMO. ESMO Open aims to operate a fast submission process with continuous publication online, to ensure that timely, up-to-date research is available worldwide and adheres to a rigorous and transparent peer review process. ESMO Open adheres to the highest possible industry standards concerning publication ethics With the widest possible reach and an international editorial board of experts and key opinion leaders, the journal aims to rapidly disseminate the best in innovative clinical and translational cancer research and improve the quality of education, prevention, diagnosis, treatment and patient care worldwide.
Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer
Tập 8 - Trang 101539 - 2023
PO-118 Impact of parity on neutron-induced mammary cancer risk in sprague-dawley rats
Tập 3 - Trang A272 - 2018
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
Tập 6 - Trang 100212 - 2021
PO-491 Frequent mTORC1 activation in head and neck squamous cell carcinomas correlates with favourable clinical outcome
Tập 3 - Trang A422 - 2018
PO-252 The circuit of oncofetal O-glycosylation, galectin-4, RTK, and MYC drives metastatic castration-resistant prostate cancer
Tập 3 - Trang A325-A326 - 2018
Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options
Tập 2 - Trang e000188 - 2017
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
Tập 7 Số 5 - Trang 100571 - 2022
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
Tập 4 - Trang e000596 - 2019